Hims & Hers Health (NYSE:HIMS) Trading Down 0.2% - Here's What Happened

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) was down 0.2% during trading on Monday . The company traded as low as $34.00 and last traded at $35.90. Approximately 8,891,770 shares were traded during mid-day trading, a decline of 32% from the average daily volume of 13,171,302 shares. The stock had previously closed at $35.95.

Analysts Set New Price Targets

A number of research firms have issued reports on HIMS. Piper Sandler lifted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Truist Financial upped their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a research report on Wednesday, February 26th. TD Cowen restated a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Needham & Company LLC increased their price target on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research report on Tuesday, February 25th. Finally, Leerink Partners boosted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $37.23.

Remove Ads

Hims & Hers Health Price Performance

The firm's 50 day moving average is $37.64 and its 200 day moving average is $27.60. The company has a market cap of $7.63 billion, a PE ratio of 78.04 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other news, insider Michael Chi sold 7,259 shares of the company's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $32.25, for a total value of $234,102.75. Following the completion of the sale, the insider now owns 184,947 shares of the company's stock, valued at approximately $5,964,540.75. This represents a 3.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 78,127 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74. Following the sale, the chief executive officer now owns 109,956 shares of the company's stock, valued at $3,256,896.72. This represents a 41.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,062,011 shares of company stock valued at $36,892,724. 17.71% of the stock is owned by corporate insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently modified their holdings of HIMS. Crewe Advisors LLC bought a new position in Hims & Hers Health during the 4th quarter valued at approximately $28,000. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after acquiring an additional 1,413 shares during the period. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health in the 4th quarter worth $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.